公开(公告)号：US20230310600A1

公开(公告)日：2023-10-05

申请号：US18020140

申请日：2021-08-09

申请人： CRAGE MEDICAL CO., LIMITED

发明人： Zonghai LI ,  Zhaohui LIAO

IPC分类号： A61K39/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C07K16/28 ,  A61P35/00 ,  A61P37/06

CPC分类号： A61K39/4611 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C07K16/2815 ,  C07K16/2818 ,  C07K16/2809 ,  A61K39/4631 ,  A61P35/00 ,  A61P37/06 ,  C12N2310/20

摘要： Provided are a method for engineering T-cells or pluripotent stem cells, as well as engineered T-cells and pluripotent stem cells. The method specifically comprises: engineering the T cells or pluripotent stem cells to obtain engineered T cell or engineered pluripotent stem cells with reduced expression, activity, and/or signaling of NKG2A. The obtained engineered T cell and a composition containing the engineered T cell can be used to treat diseases, such as cancer (tumor) and autoimmune diseases.

公开(公告)号：US20240131065A1

公开(公告)日：2024-04-25

申请号：US18278495

申请日：2022-02-25

申请人： CRAGE MEDICAL CO., LIMITED

发明人： Zonghai LI ,  Zhimin SHI

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N9/22

CPC分类号： A61K35/17 ,  A61K39/4631 ,  A61P35/00 ,  C07K16/2851 ,  C12N9/22 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/55 ,  C07K2317/622 ,  C12N2310/20

摘要： An engineered immune cell for immunotherapy, which has a relatively high persistence and/or survival rate of transplantation in a host organism, and a preparation method therefor.

公开(公告)号：US11596653B2

公开(公告)日：2023-03-07

申请号：US16164995

申请日：2018-10-19

申请人： CRAGE medical Co., Limited

发明人： Zonghai Li ,  Huiping Gao ,  Peng Wang ,  Hua Jiang ,  Huamao Wang

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  A61K48/00 ,  C07K16/30 ,  C07K14/725 ,  A61K9/00 ,  A61K31/519 ,  A61K31/664 ,  A61K31/7048 ,  A61K31/7076 ,  A61K38/20

摘要： Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

公开(公告)号：US11419895B2

公开(公告)日：2022-08-23

申请号：US16618047

申请日：2018-05-30

申请人： CRAGE medical Co., Limited

发明人： Zonghai Li ,  Peng Wang ,  Hua Jiang

IPC分类号： C07K16/30 ,  A61K35/17 ,  A61P35/00 ,  A61K38/20 ,  C07K14/725 ,  C07K16/28

摘要： Disclosed herein are methods of treating a subject exhibiting a cell that expresses Wilms tumor protein 1 (WT1). The methods typically utilize anti-WT1 antigen binding units or chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

公开(公告)号：US20240269175A1

公开(公告)日：2024-08-15

申请号：US18174565

申请日：2023-02-24

申请人： CRAGE medical Co., Limited

发明人： Zonghai LI ,  Huiping GAO ,  Peng WANG ,  Hua JIANG ,  Huamao WANG

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K31/519 ,  A61K31/664 ,  A61K31/7048 ,  A61K31/7076 ,  A61K38/20 ,  A61K48/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K31/519 ,  A61K31/664 ,  A61K31/7048 ,  A61K31/7076 ,  A61K38/2013 ,  A61K38/202 ,  A61K38/204 ,  A61K38/2073 ,  A61K48/00 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/303 ,  A01K2207/12 ,  A01K2227/105 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2740/16043

摘要： Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

公开(公告)号：US20230148586A1

公开(公告)日：2023-05-18

申请号：US17920515

申请日：2021-04-21

申请人： CRAGE MEDICAL CO., LIMITED

发明人： Zonghai LI ,  Huamao WANG ,  Huiping GAO

IPC分类号： A01N1/02 ,  C12N5/078

CPC分类号： A01N1/0221 ,  C12N5/0634 ,  C12N2500/62 ,  C12N2500/84

摘要： The present application relates to the field of cell biology. The present application provides a cryopreservation medium for cryogenic storage of a biological sample, particularly a cryopreservation medium for cryogenic storage of cells in an apheresis sample.

公开(公告)号：US20220325241A1

公开(公告)日：2022-10-13

申请号：US17634050

申请日：2020-08-10

申请人： CRAGE MEDICAL CO., LIMITED

发明人： Zonghai LI ,  Ruixin SUN

IPC分类号： C12N5/0783 ,  C07K14/725 ,  C07K14/715 ,  C07K16/24 ,  C12N15/62 ,  C12N15/85

摘要： Provided are an immune effector cell for co-expressing a chemokine receptor, a pharmaceutical composition, a kit, and a method for treating a tumor. The immune effector cell comprises a receptor that specifically recognizes claudin 18.2 and a protein that recognizes SDF-1. Further provided are an expression construct, an expression vector, and a virus. The expression construct comprises an expression of a receptor that binds to a tumor-associated antigen and an expression of the protein that recognizes SDF-1, which are connected in sequence.

公开(公告)号：US11453860B2

公开(公告)日：2022-09-27

申请号：US15532965

申请日：2015-11-30

申请人： CRAGE MEDICAL CO., LIMITED

发明人： Huamao Wang ,  Xiumei Cai ,  Hongxia Zhao ,  Bo Song ,  Yuanmei Chen ,  Yinyu Zhu

IPC分类号： C12N5/0783 ,  C12N5/10 ,  A61K39/395 ,  C12N15/63 ,  C07K14/00 ,  C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  C12N15/86 ,  A61K39/00

摘要： Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.

公开(公告)号：US11299525B2

公开(公告)日：2022-04-12

申请号：US15775769

申请日：2016-10-31

申请人： CRAGE medical Co., Limited

发明人： Zonghai Li ,  Zeyan Pan ,  Zhimin Shi ,  Bo Song ,  Peng Wang

IPC分类号： A61K35/17 ,  A61P35/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  C07K14/47 ,  A61K39/17 ,  C12N5/0783

摘要： Provided is a chimeric antigen receptor-modified immune effector cell carrying a procedural death ligand 1 (PD-L1) blocking agent. Also provided is a method for secreting and expressing a PD-L1 blocking agent using the immune effector cell as a carrier to improve the anti-tumour effect of the chimeric antigen receptor-modified immune effector cell.

公开(公告)号：US20240342305A1

公开(公告)日：2024-10-17

申请号：US18666163

申请日：2024-05-16

申请人： CRAGE MEDICAL CO., LIMITED

发明人： Huamao WANG ,  Bo SONG

IPC分类号： A61K47/68 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  G01N33/574

CPC分类号： A61K47/6879 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/395 ,  A61K48/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/7151 ,  C07K16/2809 ,  C07K16/303 ,  C07K16/46 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63 ,  A61K2039/5156 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  G01N33/57438

摘要： The present invention provides an antibody against glypican-3 (GPC3) and application thereof, and the antibody comprises a single chain antibody and humanized antibody.